bioihbjkbjnl/mcl2 huggingface dataset:
Milk Intervention Study for Brain Aging
Condition: Brain Aging
Study type: Interventional

Summary: 
      The purpose of this study is to learn if increased dairy food consumption helps brain health
      in older adults by protecting nerve cells from damage.
    

Detailed description: 
      Eating more dairy foods may improve brain health as people age by increasing the brain's
      natural defenses to protect nerve cells against chemical stress. Researchers think there may
      be a relationship between the brain's natural defense system and the amount of dairy food
      intake. Strengthening these defenses could provide beneficial protection to the brain against
      neurodegenerative age-related diseases and cognitive decline.

      Glutathione (GSH) is a metabolite in the human brain protective system. It plays a key role
      in protecting cells against oxidative stress, which is one of the major processes
      contributing to aging and neurodegeneration. Preliminary findings suggest that there may be a
      correlation between dairy food intake and GSH levels in the aging brain. Magnetic Resonance
      Spectroscopy (MRS) measures chemicals in the brain. It is a noninvasive measure of the
      effects of dairy food intake on the major protective metabolite levels in the living human
      brain in aging.

      This study involves using an MRI with special MRS scans to see if adequate dairy food intake
      may aid in enhancing cerebral protective capacity to fight against age-related disease and
      cognitive decline in the brain.

      Participants will be asked to make a total of six visits to the research site. Participation
      will last about 3 months.
    

Intervention name(s): 1% Milk; Control
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): 1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.; Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: milk; brain aging; antioxidant; glutathione; dietary intervention; brain imaging
Anaesthesia for Supratentorial Tumor Resection
Condition: Supratentorial Neoplasms
MeSH terms: Supratentorial Neoplasms
Study type: Interventional
Phase: Phase 3

Summary: 
      This is a double center, multidisciplinary, prospective, randomized, double-blind, with a
      superiority hypothesis, trial including 100 patients scheduled for resection of a
      supratentorial brain tumour under general anesthesia.
    

Detailed description: 
      On the morning of surgery, patients will be randomly allocated to one of the two following
      groups : target concentration-delivered propofol-remifentanil versus sufentanil-sevoflurane.
      The primary judgement criterion will be the rapidity of awakening, defined as the time
      between the cessation of administration of the last anesthetic until extubation. Several
      secondary judgement criteria related to quality of postoperative recovery and complications
      will be collected. The hypothesis tested is a 30% reduction of the time necessary to extubate
      patients after cessation of anesthetic delivery in the propofol-remifentanil group. Based on
      previous works, using an risk of 20 % and an of 5 %, 100 patients must be included in this
      study (50 or each group). Statistical analysis will be performed by WILCOXON MANN, WHITNEY
      and X2 tests based on the type of variables.

      The results of this study should provide a first choice anaesthetic regimen to optimize
      postoperative recovery of neurosurgical patients undergoing resection of supratentorial brain
      tumours. They will contribute to the improvement in the management of patients suffering from
      cancer.
    

Intervention name(s): Comparison of two anesthetics protocol
Intervention type(s): Drug
Intervention description(s): Comparison of two anesthetics protocol
Intervention MeSH terms: Anesthetics
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: supratentorial brain tumors; propofol; sevoflurane; remifentanil; sufentanil.
Efficacy of Treatment for Panic Disorder
Condition: Panic Disorder
MeSH terms: Panic Disorder
Study type: Observational

Summary: 
      The purpose of these questionnaires is to give us an overview of how panic has affected your
      life and perhaps also to give us some clues about things that may have set you up to
      experience panic.
    

Detailed description: 
      For us to evaluate the efficacy of our treatment programs, we are interested in your
      responses before and after treatment. We use two methods to evaluate the efficacy of our
      treatments: questionnaires and interviews with a member of the Anxiety Disorders Clinic. As
      part of standard clinic procedure, each person in the program completes an in-person
      interview with a staff member who will determine your suitability for treatment. If you have
      received this questionnaire packet, it is likely that your concerns will be appropriately
      addressed in the Anxiety Disorders Clinic. The purpose of the questionnaire packet is to
      assess the severity of your panic disorder; its impact on your functioning, and factors that
      may contribute to the onset or maintenance of your panic (e.g., depression, anxiety
      sensitivity). We will ask you to complete this questionnaire again when you have completed
      your treatment along with a brief telephone interview with a staff member of the Anxiety
      Disorders Clinic.
    

Observational model: Cohort
Sampling method: Probability Sample
Study population: 
        Patients referred to the Anxiety Disorders Clinic, Vancouver, who receive a primary
        diagnosis of Panic Disorder, and are accepted for treatment at the clinic.
      
Keywords: Panic Disorder; Anxiety; Treatment efficacy
Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia
Condition: Cardiomyocyte Apoptosis
Study type: Observational

Summary: 
      Retrograde cardioplegia during heart surgery is associated with inadequate myocardial
      protection. In experimental animal study retrograde cardioplegia induces more cardiomyocyte
      apoptosis when compared to antegrade cardioplegia. 20 volunteer patients under going elective
      aortic valve surgery will be divided in to two groups: 10 patients receiving only antegrade
      cardioplegia and 10 patients receiving only retrograde cardioplegia. Pre- and
      post-operatively cardiac MRI and cardiac ultrasound will be performed. During the surgery
      ventricular muscle samples will be taken in order to assess cardiomyocyte apoptosis. Aims of
      the study: 1. whether the cardiomyocyte apoptosis is significantly more induced after
      retrograde cardioplegia than antegrade cardioplegia, 2. whether the amount of apoptotic
      cardiomyocytes correlates to conventional markers of myocardial injury after cardiac surgery,
      3. whether the extent of irreversible myocardial damage by apoptosis correlates to
      post-ischemic contractile dysfunction after cardiac surgery, as measured with
      echocardiography, 4. whether the amount of cardiomyocyte apoptosis correlates to long term
      outcome and cardiac function as measured with MRI.
    


Intervention name(s): Ventricle muscle tissue samples
Intervention type(s): Procedure
Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        20 patients (male and female) undergoing elective aortic valve replacement surgery due to
        aortic valve stenosis or combined aortic valve disease in Turku University Hospital,
        Department of Surgery.
      
Biospecimen description: 
      Transmyocardial needle biopsies
    
Keywords: Cardiac MRI; Cardiac ultrasound; Cardiac surgery
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions
Condition: Hypertension
MeSH terms: Hypertension
Study type: Interventional
Phase: Phase 1

Summary: 
      To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting
      Conditions.
    


Intervention name(s): Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA); Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Intervention type(s): Drug; Drug
Intervention MeSH terms: Lisinopril
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
The Effect of HealthWear on Short-Term Weight Loss
Condition: Weight Loss; Obesity
MeSH terms: Body Weight; Weight Loss
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this study is to examine the effect of a computer tracking system and energy
      expenditure device on weight loss in adults.
    


Intervention name(s): behavioral weight loss
Intervention type(s): Behavioral
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Eosinophilic Airway Inflammation and Mepolizumab
Condition: Asthma
MeSH terms: Inflammation
Study type: Interventional

Summary: 
      A drug (mepolizumab) that reduces allergic inflammation will affect the function of allergy
      cells called eosinophils which are produced by the body in response to allergen exposure.
    


Intervention name(s): mepolizumab
Intervention type(s): Biological
Intervention description(s): up to three monthly doses of 750mg i.v. mepolizumab
Other intervention name(s): anti-interleukin 5
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: asthma; allergic inflammation; interleukin-5
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Condition: Allergic Rhinoconjunctivitis
MeSH terms: Conjunctivitis
Study type: Interventional
Phase: Phase 2

Summary: 
      Based on EMA (European Medicines Agency) new guidelines on the clinical development of
      products for immunotherapy for the treatment of allergic diseases the aim of this study is to
      establish a dose-response relationship for clinical efficacy of Phleum pratense pollen
      extract subcutaneous vaccine.
    

Detailed description: 
      In adherence to EMA guidelines, the Phase I Clinical trial was carried out using Phleum
      pratense extract in depot presentation using 3 different dose escalation scheme. The
      objective was to compare tolerance and safety of the three dose escalation scheme as well as
      to determine the maximum dose tolerated by the population.

      Once the range of tolerated doses was established, and following the strict norms of the EMA,
      a Phase II dose response clinical trial was designed wherein the efficacy of subcutaneous
      immunotherapy in depot presentation could be compared in 5 different doses. One of these
      doses will be the MTD established by the population in the first study, another will be lower
      than this dose, and three will be greater than it. The dose escalation scheme to be tested
      was chosen based on the results of the aforementioned clinical trial. As dictated by EMA
      norms, a control placebo will be used.
    

Intervention name(s): Allergovac Depot; Allergovac Depot; Allergovac Depot; Allergovac Depot; Allergovac Depot; Placebo
Intervention type(s): Biological; Biological; Biological; Biological; Biological; Biological
Intervention description(s): Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.; Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.; Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.; Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.; Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.; Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other intervention name(s): Allergovac; Allergovac; Allergovac; Allergovac; Allergovac; Allergovac
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Allergy; Allergic rhinoconjunctivitis; Subcutaneous Immunotherapy; Phleum pratense pollen extract
Colonoscopy Educational Video Upon Inner City Population
Condition: Other Surgical Procedures
Study type: Interventional

Summary: 
      Background:

      The investigators assessed the use of a colonoscopy instructional video to improve both bowel
      preparation and education prior to procedure. Preceding studies have been vague, pinning
      patient education via diagrams and text as both pivotal and useless for compliance in bowel
      preparations. These studies however lacked assessment of comprehension prior to procedure.

      Methodology:

      This is a prospective study of diverse, inner city outpatient university center, first time
      colonoscopy patients given 1 of 2 on-site videos and written/verbal instruction.
      Experimentals saw a 5 min video on the purpose of colonoscopy, bowel preparation,
      pre-colonoscopy diet, and proper laxative use. Controls saw a 5 min video from the same
      spokesperson on upper endoscopy; which was trivial. Both groups were given a quiz within 30
      days of the colonoscopy on demographics, and 14 test questions about colonoscopy and
      preparation. Subsequently, endoscopists used the additive Ottawa scale to rate quality of
      preparation (range 0-14) via: fluid (0=sm,1=mod, 2=lg) and cleanliness in each the right, mid
      and rectosigmoid colon, (0=excellent, 1=good, 2=fair, 3=poor, 4=inadequate).
    


Intervention name(s): Colonoscopy Educational Video; Placebo Educational Video
Intervention type(s): Other; Other
Intervention description(s): Brief Video utilization to assess comprehension and evaluation bowel preparation quality; Brief Video utilization to provide placebo information and evaluation bowel preparation quality
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
Condition: Psoriasis
MeSH terms: Psoriasis
Study type: Interventional
Phase: Phase 2

Summary: 
      The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and
      Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety
      Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through
      24 weeks of treatment
    


Intervention name(s): Placebo (fasted); BI 25 mg (fasted); BI 50 mg (fasted); BI 100 mg (fasted); BI 200 mg (fasted); Placebo (fed); BI 400 mg once daily (fed); BI 200 mg twice daily, 400 mg total (fed)
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).; 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).; 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).; 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).; 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).; 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.; 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.; 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Efficacy and Neuroimaging Mechanisms of Smoking Cessation in China
Condition: Cigarette Smoking; Psychological Interventions; Smoking Cessation
Study type: Interventional

Summary: 
      This proposed project is to assess the efficacy of CBT-based digital smoking cessation
      interventions in China, as well as explore its neuroimaging mechanisms.
    


Intervention name(s): Cognitive behavior therapy
Intervention type(s): Behavioral
Intervention description(s): Participants will receive CBT intervention for smoking cessation via "wechat"-based mini-program developed by a professional team.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Elaboration of New Generation Snacks
Condition: Snack Food
Study type: Interventional

Summary: 
      It is a blind randomized clinical trial of nutritional intervention in humans with a snack
      (seaweeds and carob), compared to a control snack without the bioactive ingredients studied
      but of similar nutritional composition, to evaluate the effect on the lipid profile, glycemia
      and Insulin resistance.
    

Detailed description: 
      The design will consist of a double-blind randomized study in adult subjects with metabolic
      syndrome, who will consume snack (enriched in seaweeds and carob) (50 g / day) vs.
      conventional snack for 8 weeks.

      All the next parameters will be measured/calculated at basal time and after 8 weeks of
      intervention. The next biochemical parameters will be measured: Total cholesterol, LDL
      cholesterol, HDL, triglycerides will be analyzed using an enzyme-colorimetric method (Roche
      Diagnostics , Mannheim, Germany). Glucose will be determined by the method of glucose oxidase
      (Glucose analyzer 2, Beckman Instruments, Fullerton, California), insulin will be determined
      by Elisa (ELISA Diagnostic Corporation, Los Angeles, CA) and HOMA will be calculated by the
      formula Matthew et al. , 1985 (HOMA = (glucose * insulin) / 22.5). Body weight and fat mass
      by bioimpedance will be measured, too. Blood pressure (Systolic and diastolic blood pressure)
      will be measured, too. A diet records for 3 days and a satiety scale will be performed at the
      beginning and end of the intervention period.
    

Intervention name(s): Active snack food; Control snack food
Intervention type(s): Other; Other
Intervention description(s): snack enriched with seaweeds and carob; the same snack food without seaweeds and carob
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: carob; seaweed; snack food; obese subjects
Co-existent Obstructive Sleep Apnea (OSA) and Obesity: Finding Non-exercise Activity Thermogenesis (NEAT) Targets for Intervention
Condition: Childhood Obesity; Childhood Obstructive Sleep Apnea
MeSH terms: Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Obesity; Pediatric Obesity
Study type: Observational

Summary: 
      Rationale: Obesity is an increasing childhood epidemic in Canada. Obstructive sleep apnea
      (OSA) is a complication of obesity which causes cardiovascular disease, reduced quality of
      life, and premature death. While the complex interactions between obesity and OSA are not
      entirely clear, we hypothesize that these conditions may compound each other by:

        1. decreasing physical activity and total energy expenditure by reducing both non-exercise
           physical pursuits (NEAT- non-exercise activity thermogenesis) and purposeful physical
           activity.

        2. alterations in the secretion of appetite-controlling hormones, which may lead to
           increases in energy intake.

      Objective: To determine whether the presence of both obesity and OSA in children is
      associated with a decrease in physical activity and alterations in appetite-regulating
      hormones greater than those seen in either condition alone or compared to controls.

      Methods: Comparison of children 10-17 years with obesity and OSA, obesity alone, OSA alone
      and neither condition, for the following outcomes: (1) NEAT (kcal/day) (2) Physical activity
      behavior, appetite regulating hormone profile and self-report appetite assessment.

      Unique Aspects: This study combines expertise in sleep medicine, exercise physiology and
      obesity. Conclusions from this study will better characterize this high-risk clinical
      population so that innovative strategies targeting improvements in lifestyle behaviors can be
      developed.
    


Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Subjects will be recruited from those scheduled to undergo polysomnography in the sleep
        laboratory at the Children's Hospital of Eastern Ontario
      
Biospecimen description: 
      urine
    
Keywords: Sleep; Overweight; Physical activity; Appetite; NEAT